Abstract
Radical cystectomy with bilateral pelvic lymphadenectomy and trimodality bladder-sparing therapy or TMT, are both curative options for patients with nonmetastatic muscle invasive bladder cancer. Patients should be afforded the opportunity for a multidisciplinary evaluation with equipoise in discussing these options for eligible patients. We discuss the barriers to broader acceptance and utilization of TMT and encourage support of clinical trials of TMT.
Original language | English (US) |
---|---|
Pages (from-to) | 35-38 |
Number of pages | 4 |
Journal | Urologic Oncology: Seminars and Original Investigations |
Volume | 41 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2023 |
Keywords
- Barriers
- Bladder cancer
- Chemoradiation
- Radical cystectomy
- Trimodality therapy
ASJC Scopus subject areas
- Oncology
- Urology